Valuation: Pliant Therapeutics, Inc.

Market Cap 69.35M 59.38M 55.4M 50.84M 95.53M 6.64B 97.41M 657M 256M 3.33B 260M 255M 11.01B P/E 2026 *
-0.76x
P/E 2027 * -0.82x
Enterprise Value -48.69M -41.69M -38.9M -35.69M -67.07M -4.66B -68.39M -461M -180M -2.33B -183M -179M -7.73B EV / Sales 2026 *
-
EV / Sales 2027 * 9.19x
Free-Float
97.77%
Yield 2026 *
-
Yield 2027 * -
08-18 Pliant Therapeutics, Inc. Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For Treatment Of ICI-Refractory Solid Tumors CI
08-11 Pliant Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-13 Pliant Therapeutics, Inc. Appoints Flavia Borellini and Robert Iannone to Its Board of Directors CI
05-22 Pliant Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 11:30 AM
05-11 Pliant Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-30 Pliant Therapeutics Announces First Patient Dosed in Fortify Phase 1B Indication Expansion Trial Evaluating Pln-101095 in Patients with Ici-Refractory Solid Tumors CI
04-18 Pliant Therapeutics Announces Updated Data from Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors CI
04-18 Pliant Therapeutics says PLN-101095 generally well tolerated; most common TRAE was rash, one grade 3 TRAE observed RE
04-17 Pliant Therapeutics, Inc. Announces Board and Committee Retirements CI
03-18 Pliant Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Pln-101095 in Patients with Solid Tumors CI
03-18 Pliant Therapeutics announces upcoming presentation of phase 1 clinical trial of PLN-101095 in patients with solid tumors at the 2026 American Association for Cancer Research annual meeting RE
03-11 Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
03-09 Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 CI
1 day-4.27%
1 week+3.70%
Current month+7.69%
1 month+4.67%
3 months-6.67%
6 months-9.68%
Current year-8.20%
1 week 1.07
Extreme 1.07
1.23
1 month 1.02
Extreme 1.02
1.23
Current year 1.02
Extreme 1.02
1.44
1 year 1.02
Extreme 1.02
1.95
3 years 1.02
Extreme 1.02
19.62
5 years 1.02
Extreme 1.02
36.64
10 years 1.02
Extreme 1.02
43.92
Manager TitleAgeSince
Chief Executive Officer 60 2016-01-31
Director of Finance/CFO 49 2018-11-30
Chief Operating Officer 45 2025-12-09
Director TitleAgeSince
Director/Board Member 60 2016-01-31
Director/Board Member 74 2017-07-31
Chairman 56 2018-04-30
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Free

Director

60,000 0.0969%
7/9/26 Free

Director

60,000 0.0969%
6/11/26 Free

Director

70,000 0.1130%
Change 5-day change 1-year change 3-year change Capi.($)
-4.27%+3.70%-21.68%-93.33% 69.35M
-2.81%+2.93%+76.40%+127.73% 1,109B
-2.21%+2.02%+49.50%+55.01% 644B
-1.56%+4.39%+25.19%+74.39% 463B
-1.45%+3.10%+39.47%+43.96% 371B
-1.12%+1.98%+21.39%+38.73% 301B
-0.64%+4.72%-0.40%+12.43% 256B
-1.95%+3.80%+46.31%+65.66% 234B
-0.46%+0.05%-17.20%-53.24% 205B
-2.82%+3.84%+20.81%+89.04% 178B
Average -0.94%+3.07%+23.98%+36.04% 376.11B
Weighted average by Cap. -0.26%+3.26%+42.62%+69.93%

Financials

2026 *2027 *
Net sales - 3M 2.57M 2.4M 2.2M 4.13M 287M 4.21M 28.43M 11.08M 144M 11.26M 11.02M 476M
Net income -90.67M -77.63M -72.43M -66.46M -125M -8.68B -127M -859M -335M -4.35B -340M -333M -14.39B -94.16M -80.62M -75.22M -69.02M -130M -9.01B -132M -892M -348M -4.52B -354M -346M -14.95B
Net Debt -118M -101M -94.3M -86.53M -163M -11.29B -166M -1.12B -436M -5.66B -443M -434M -18.74B -41.79M -35.78M -33.39M -30.64M -57.57M -4B -58.7M -396M -154M -2B -157M -154M -6.64B
Logo Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Employees
49
Date Price Change Volume
26-08-20 US$1.120 -4.27% 401,768
26-08-19 US$1.170 +1.74% 681,752
26-08-18 US$1.150 +4.55% 1,373,048
26-08-17 US$1.100 +2.80% 590,771
26-08-14 US$1.070 -0.93% 235,026
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
1.120USD
Average target price
2.500USD
Spread / Average Target
+123.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PLRX Stock